Clinical Trial

Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).
Protocol Amendment History 4 changes
critical Recruitment opened 2026-06-05
notable Trial sites expanded: 12 -> 15 locations 2026-06-05
notable Sponsor changed: Honeybrains Biotech LLC -> HB BioTech, LLC 2026-04-26
critical Primary endpoint(s) modified 2026-04-07
Trial Details
NCT Number NCT07499440
Lead Sponsor HB BioTech, LLC
Conditions PTSD, Mental Illness
Enrollment 200 participants
Start Date 2026-06
Primary Completion 2027-09 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06